TB-500 side effects have not been measured in human trials.
The researchers wanted a shorter chain to retain a role in moving cells toward wounds. Later thymosin beta-4 studies raised concern about tumor growth, while your risks from TB-500 remained unmeasured.
TB-500 side effects have no measured rate for people like you
You don't have human findings that show how often TB-500 causes harm. A completed trial comparing TB-500 with other care is still missing [5].
The closest safety study gave thymosin beta-4, the longer protein, through a vein. This thymosin beta-4 Phase 1 study was an early test aimed mainly at finding unwanted effects.
Researchers tested up to 1260 milligrams across 14 days in 40 healthy volunteers [6]. No serious harm or effects requiring lower treatment amounts were reported.
The volunteers were healthy and watched closely during that short study. Those findings don't settle what happens in older people with injuries or illness.
The volunteers didn't receive TB-500, and treatment went directly into a vein. Shots of the copied chain placed beneath skin or within muscle weren't tested for safety there.
Even nausea has no measured human rate for the copied chain. You can't put a reliable chance of harm on those personal accounts.
Cell movement and added blood vessels may support healing or supply a tumor. Human tests still need to answer whether the copied chain carries that possible risk.
TB-500 cancer concerns arise from laboratory findings about the longer protein
Several cancers have high thymosin beta-4 levels linked to the cancer spreading [7]. More moving cells and new vessels could, in theory, support a growing tumor [7].
Human pancreatic cancer cells in dishes grew more and entered nearby tissue more readily with thymosin beta-4 [8]. The pancreas is a gland near your stomach; researchers tested its cancer cells, rather than treating people.
These cell findings don't establish that TB-500 caused cancer in anyone receiving treatment [5][7]. Your possible risk remains unresolved because human harm from the copied chain hasn't been measured.
TB-500 blood vessel hopes also raise a question about feeding tumors
Thymosin beta-4 helped more vessels grow and encouraged movement by the cells lining vessels [10]. You need blood reaching a wound to nourish the damaged tissue and bring oxygen.
A tumor needs that supply too, so added vessels might support cancer growth [7][10]. The concern comes from laboratory findings; harm from the copied chain remains unproved in people.
You need to know where new growth happens, not only whether growth increases. Human safety studies still haven't answered that question for the copied chain.
TB-500 was not the treatment in the reassuring human safety study
Completed human trials haven't established TB-500's safety compared with other care [5]. The thymosin beta-4 study often offered as reassurance gave thymosin beta-4 directly into a vein.
Amounts reached 1260 milligrams during that early Phase 1 safety test [6]. Serious harm wasn't reported, but those volunteers received a different substance from the copied chain.
Questions about tumor growth and extra blood reaching tumors remain open [7][8]. Testing another protein doesn't measure your chance of those harms from the copied chain.
TB-500 has unanswered risks from both treatment and uncertain bottle contents
You still lack a finished trial comparing human TB-500 treatment against other care [5]. An early safety study, Phase 1, found thymosin beta-4 tolerated up to 1260 milligrams [6].
That trial leaves your chance of harm from the shorter chain unknown. Additional vessels feeding a tumor remain a possible risk needing human tests [7].
Research bottles may hold unwanted material or a substance different from the label [5]. You can't judge reported symptoms confidently when the person may have received something else.
TB-500 use over years has not been tested for human safety
Studies haven't answered what years of TB-500 use might mean for your health [5]. The longest human comparison study gave thymosin beta-4 through a vein for 14 days [6].
Mice received 150 micrograms twice weekly for 6 months around their belly organs [9]. Each gram contains a million micrograms, and the treatment was the longer protein.
A short human test and longer animal work can't settle your long-term safety. Possible support for tumor growth adds an unanswered concern about prolonged use [7].
TB-500 repair claims leave failed animal tests and supply risks to explain
Mice grew more muscle fibers after thymosin beta-4 without gaining muscle strength [9]. Their heart pumping and scarring didn't improve either, despite the new growth.
Pigs given thymosin beta-4 gained no protection from heart damage caused by stopping and restoring blood flow [14]. These failures show why more growth doesn't necessarily mean useful healing for you.
Separate from those tests, research bottles may contain something other than the named substance [5]. That supply problem also makes personal reports of harm or benefit hard to judge.
Research bottles lack the same checks as approved medicines
Research supplies are made outside the production checks required for approved medicines [5]. A bottle named TB-500 might hold the longer protein or another substance instead.
You can't tell the contents or purity by reading that label alone. If a bottle holds the longer protein, a reported change may concern that protein [5].
Human studies haven't yet measured the chance of harm from TB-500 itself. Uncertain contents add another reason that personal reports can't establish safety for you.
The rules for pharmacy ingredients address an ingredient's legal use when a pharmacy prepares medicine. Your prescription alone doesn't answer whether the pharmacy can legally use TB-500.